^
Association details:
| Biomarker: | DNMT3A mutation + SF3B1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Published date:
07/13/2020
Excerpt:
Among lenalidomide-treated patients...The proportion of patients achieving RBC-TI ≥8 weeks was nominally higher in those with DNMT3A mutations than in those without (43.8% vs. 24.6%; p = 0.133). RBC-TI ≥8 weeks was achieved by 42.9% of patients with both DNMT3A and SF3B1 mutations (which co-occurred in most patients)
DOI:
10.1038/s41375-020-0961-3
Source:
Title:
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
Excerpt:
Of 139 pts treated with Len as monotherapy or in combination for at least 2 cycles included, 118 (85%) had MDS...The combination of the following abnormalities predicted resistance (ASXL1, TET2, NK), (DNMT3A, SF3B1), (TP53, del(5q)+CK), (STAG2, IDH 1/2, NK), (EZH2, NK), (BCOR/ BCORL1, NK), (JAK2, TET2, NK), (U2AF1, +/- ETV6, NK)....Only TP53/CK mutations predicted resistance to Len in del(5q) pts.
DOI:
10.1182/blood-2018-99-114681
